Fostamatinib for immune thrombocytopenic purpura in adult patients: A systematic review and meta‐analysis

Abstract

Immune thrombocytopenic purpura (ITP) is an immune disorder characterized by thrombocytopenia. Fostamatinib is an orally administered spleen tyrosine kinase inhibitor intended to treat refractory ITP. To evaluate the efficacy and safety of fostamatinib as a subsequent‐line therapy for ITP in adults. We searched four electronic databases for primary studies of any design. Primary efficacy outcomes included proportions of patients achieving overall (≥30 × 10⁹ cells/L), partial (≥50 × 10⁹ cells/L), and stable (as defined in original studies) platelet response. Safety outcomes included rescue medication use and other adverse events. We used narrative synthesis and Mantel–Haenszel random effect meta‐analysis to summarize results. Our systematic review included 11 studies for analyses (n = 722). Weighted mean proportions of patients achieving overall, partial, and stable responses with fostamatinib treatment were 0.70 [0.62, 0.76], 0.48 [0.36, 0.61], and 0.28 [0.16, 0.44], respectively. Fostamatinib was favored over placebo for partial (relative risk [RR] = 3.04, 95% confidence interval [CI] [1.53, 6.06]) and stable (RR = 6.43, 95% CI [1.58, 26.23]) responses. Patients on fostamatinib required less rescue medication and were more likely to experience hypertension. Fostamatinib is a viable subsequent‐line therapy option for refractory ITP. Given the heterogeneous data and large number of small studies, these results should be interpreted cautiously.

1. INTRODUCTION

Immune thrombocytopenic purpura (ITP) is an acquired immune disorder characterized by decreased platelet counts and increased bleeding risk [1]. Treatment of ITP aims to increase and maintain the platelet count to stop or prevent bleeding. First‐line treatments include corticosteroids, intravenous immunoglobulin, and anti‐D immunoglobulin [1]. These interventions provide rapid benefits that are often transient. Second‐line treatments include splenectomy, thrombopoietin receptor agonists (TPO‐RAs), and rituximab [1].

Splenectomy is known for its potential to induce long‐term remission and has a high initial response rate. However, splenectomy introduces risks of surgical complications and infection and requires lifetime postsplenectomy care [2, 3]. TPO‐RAs may improve bone marrow platelet production, and rituximab targets B lymphocytes to reduce ITP‐associated autoantibody production [4, 5]. Both are widely used treatments, are expensive, and rarely induce long‐term, off‐therapy improvements in the platelet count [6].

Fostamatinib is an orally administered spleen tyrosine kinase (SYK) inhibitor that received U.S. Food and Drug Administration approval in 2018 for treatment in adult patients with refractory ITP [7]. The target of fostamatinib, SYK, is an essential protein involved in the phagocytosis of platelets that antibodies have opsonized [8]. This therapy has demonstrated potential for the treatment of patients with refractory ITP without increasing the risks of bleeding [9]. This paper aims to synthesize the evidence for fostamatinib as a subsequent‐line treatment for ITP with regard to increased platelet count and adverse events (AEs).

1.1. Objectives

To systematically review the safety and efficacy of fostamatinib as a subsequent‐line treatment for ITP in adults.

2. METHODS

This review was prospectively registered on PROSPERO (CRD42023425690) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines (checklist in Supporting Information 1) [10].

2.1. Eligibility criteria

We included all primary studies (trials, observational cohorts, and case series) of adult patients (≥18 years of age) with ITP who were treated with fostamatinib. We did not exclude based on language or abstract‐only publications. Studies were excluded if patients were on concomitant medication that altered platelet function or coagulation.

2.2. Information sources and search strategy

Electronic database searches from inception to December 12, 2023, were conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL). Key terms included “fostamatinib” and “ITP.” Full search strategies are available in Supporting Information 2. The references of relevant review articles captured in the literature search were manually reviewed to identify any articles not identified in the original search strategy.

2.3. Study selection and data extraction

Study records were imported into Covidence (Veritas Health Information). Screening for eligible records and data extraction (study characteristics and outcome data) were conducted in duplicate by pairs of independent reviewers (Roger Kou, Lucy Zhao, and Daniel Tham). Disagreements were resolved by consensus.

2.4. Outcomes

Primary efficacy outcomes included the proportion of patients who achieved an overall platelet response (≥30 × 10⁹ cells/L), partial response (≥50 × 10⁹ cells/L), or a complete platelet response (as defined by the original study) while receiving fostamatinib. Secondary efficacy outcomes included time to and duration of response. Safety outcomes included rescue medication use, venous thromboembolism (VTE), major, minor, and clinically relevant nonmajor bleeding (CRNMB) events as defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria [11, 12], and other AEs (hypertension, diarrhea, nausea, neutropenia, dizziness, fatigue, abdominal pain, transaminitis, and infection).

2.5. Risk of bias assessment

The risk of bias assessment was conducted using the RoB2 tool for randomized controlled trials (RCTs) and the ROBINS‐I tool for observational studies [13, 14]. We evaluated the methodological quality of the case series using guidance developed by Murad et al. [15]. Abstracts were excluded from the risk of bias assessments.

2.6. Statistical analysis

We reported the primary and secondary outcomes by narrative synthesis and pooled proportion estimates (with associated 95% confidence interval [CI]). Case series and abstract‐only publications were excluded from all primary meta‐analyses. Secondary analyses included these articles and results were compared qualitatively to primary analysis results. Logit transformation was applied to proportions. The weighted mean proportions of patients with partial, overall, and stable responses to fostamatinib treatment were pooled separately using random effects models. We conducted additional post hoc comparisons of fostamatinib to placebo using Mantel–Haenszel random effects models to calculate risk ratios for efficacy and safety outcomes when possible. The restricted maximum likelihood method was used to estimate the between‐study variance, τ ². Heterogeneity among studies was tested with the Cochran Q statistic, qualified by visual inspection of the forest plots, and quantified by indicator I ². An I ² <30% was considered nonsignificant heterogeneity, I ² of 30%–70% as moderate heterogeneity, and I ² >70% as considerable heterogeneity. All p values <0.05 were considered statistically significant. All meta‐analyses were performed using R software (version 4.1.2).

3. RESULTS

3.1. Study selection

We identified 2118 articles through our literature search, of which 91 were examined for full‐text review and 11 were included for analysis (Figure 1). These included two RCT reports (representing three separate trials), five observational cohorts (three abstracts and one follow‐up to the RCTs), and four case series (one of which was an abstract), representing a total of 722 patients. Among the RCTs, one study included results from two separate trials (FIT‐1 and FIT‐2) [16]. For meta‐analyses, data from FIT‐1 and FIT‐2 were treated as distinct studies when it was possible to extract individual study data (e.g., for partial, stable, and rescue medication use). The FIT‐3 study, which included follow‐up data of patients from these two trials, was only used in analyses when data from the original trials was unavailable (pooled proportion of overall response). Secondary analyses that include data from abstracts and case series are reported in Table S1.

FIGURE 1.

Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) flowchart. RCT, randomized controlled trial.

3.2. Risk of bias

All RCTs were judged to be low risk for bias for all outcomes. All nonrandomized studies were judged to be at high risk for bias primarily due to a lack of confounder adjustment. Figure 2 illustrates the traffic‐light plots for full‐text RCTs and observational studies [17]. All case series were determined to have low methodological quality. Publication bias was suspected, given the high number of small studies.

FIGURE 2.

Traffic‐light plots for (A) randomized and (B) nonrandomized studies, not including case series or abstracts. RCT, randomized controlled trial.

3.3. Description of study participants

Patient ages ranged from 19 to 100 years, with a duration of ITP between <1 and 53 years. Most studies included patients who had undergone a median of 3 prior therapies for ITP. These prior therapies were categorized accordingly: corticosteroids, IVIG/IV Anti D, TPO agents, immunosuppressants, splenectomy, rituximab, danazol, chemotherapy, and others. All studies with available data reported median baseline platelets at therapy initiation of <40 × 10⁹ cells/L. Patients in all RCTs were permitted to take one concomitant ITP medication throughout the study [16, 18]. Table 1 summarizes the characteristics of the studies included in this review.

TABLE 1.

Characteristics of included studies. ^a

Study, year	Design	Funding	Patients on fostamatinib	Country	Age, years b	Male, n (%)	Duration of ITP, years b	Prior treatments b , c	Splenectomy (%)	Baseline platelets, ×109 cells/L b
Kuwana, 2023 [18]	Phase III RCT	Industry	22	Japan	61 (25–81)	4 (18)	12 (1–41)	2 (1–7) d	5 (23)	19 (3–28)
Bussel, 2018 [16]	Two Phase III RCTs	Industry	101	International	54 (20–88)	40 (40)	8.7 (0.3–53)	3.0 (1–13)	34 (34)	16.1 (1–51)
	FIT‐1		51	North America, Europe, Australia	57 (20–88)	21 (41)	7.5 (0.6–53)	3 (1–9)	20 (39)	16.2 (1–51)
	FIT‐2		50	Europe	50 (21–82)	19 (38)	8.8 (0.3–50.2)	3 (1–13)	14 (28)	15.9 (1–33)
Dranitsaris, 2023 [30]	Retrospective cohort	Industry	51	United States	59 (21–88)	16 (31)	4.5 (1–21)	3 (2–6)	20 (39)	21 (4–46)
Bussel, 2022 [23, 36]	Retrospective cohort abstract	Industry	318	NR	67 (19–100)	NR	NR	NR	NR	32 (NR)
Moezi, 2022 [37]	Retrospective cohort abstract	Industry	46	United States	58 (NR)	16 (35)	NR	2 (NR)	16 (35)	19 (3–70)
Cooper, 2021 e [20]	Prospective cohort (FIT‐3)	Industry	146	NR	53 (20–88)	58 (40)	8.4 (<1–53)	3 (1–13)	51 (35)	16 (NR)
Podolanczuk, 2009 [19]	Prospective cohort	Industry	16	United States	66 (31–81)	6 (38)	9 (1–≥29)	5 (2–≥3)	11 (69)	16 (2–28)
Grantab, 2022 [38]	Case series abstract	NR	5	NR	77 (56–94)	3 (60)	5 (0.6–18)	2 (2–5)	0 (0)	14 (<10–26)
Liu, 2022 [21]	Case series	None	7	United Kingdom	80 (63–94)	3 (43)	6 (0.5–30)	2 (1–6)	1 (14)	25 (10–193)
Mehta, 2022 [22]	Case series	Industry	5	NR	79 (60–90)	4 (80)	6 (0.2–8.3)	2 (1–6)	NR	39 (17–59)
Hughes, 2021 [39]	Case series	NR	5	NR	69 (22–75)	3 (60)	6 (1–8)	3 (3–6)	1 (20)	35 (4–264)

Abbreviations: ITP, immune thrombocytopenic purpura; RCT, randomized controlled trial.

^a NR, not reported.

^b Unless otherwise noted, values are the median (range [i.e., minimum, maximum]).

^c Prior unique treatments counted as falling within the following categories: corticosteroid, IVIG/IV Anti D, thrombopoietin (TPO) agents, immunosuppressants, splenectomy, rituximab, danazol, chemotherapy, and other (i.e., dapsone).

^d Kuwana et al. report splenectomy separately and is not included in this count.

^e Cooper et al. (FIT‐3) is a prospective cohort that includes follow‐up of participants from the FIT‐1 and FIT‐2 randomized trials.

3.4. Description of fostamatinib dosing and schedule

All studies, except for the open‐label pilot [19], initiated fostamatinib at 100 mg BID, with dose modifications up to 150 mg BID permitted. Dose modification protocols were clearly described in all trials [16, 18] and the two prospective studies (i.e., escalation permitted after 4 weeks, depending on platelet count) [19, 20]. The reported duration of treatment varied between studies; all trials used fostamatinib for a minimum of 24 weeks.

3.5. Efficacy outcomes

3.5.1. Platelet count response on fostamatinib

The proportion of patients achieving an overall platelet count response (≥30 × 10⁹ cells/L) was 0.70 (95% CI: 0.62, 0.76; I ² = 0%; N = 162). The pooled proportion of partial responders (≥50 × 10⁹ cells/L) was 0.48 (95% CI: 0.36, 0.61; I ² = 89%; N = 139). The pooled proportion of stable responders was 0.28 (95% CI: 0.16, 0.44, I ² = 95%; N = 139). Table 2 summarizes the pooled proportions for platelet response outcomes. Definition of stable responses was similar across the three RCTs and more varied across the observational studies; definitions are available in Table S2. Table S3 summarizes platelet response data and includes forest plots to illustrate these results (Figures S1–S3).

TABLE 2.

Summary of pooled proportions for efficacy and safety outcomes on fostamatinib. ^a

Outcome	Contributing studies	Number of patients	Pooled proportion	95% CI	I 2 c
Overall response	2	162	0.70	0.62, 0.76	0%
Partial response	4	139	0.48	0.36, 0.61	53%
Stable response	4	139	0.28	0.16, 0.44	67%
Any adverse event b	3	174	0.86	0.80, 0.91	0%
Severe adverse event b	2	123	0.15	0.10, 0.22	0%
Adverse event causing treatment withdrawal b	3	174	0.10	0.06, 0.15	0%
Any bleeding b	2	123	0.08	0.03, 0.20	52%
Rescue therapy b	4	190	0.30	0.24, 0.37	30%
Hypertension b	4	190	0.24	0.13; 0.40	67%
Diarrhea b	4	190	0.30	0.21, 0.40	43%
Nausea b	4	190	0.16	0.10; 0.24	37%
Neutropenia b	3	174	0.07	0.02; 0.21	64%
Dizziness b	2	117	0.11	0.07; 0.18	0%
Fatigue b	3	168	0.15	0.04; 0.44	87%
Abdominal pain	3	89	0.09	0.04; 0.22	38%
Transaminitis b	3	139	0.15	0.07; 0.29	61%
Infection b	2	123	0.17	0.11; 0.24	0%

Abbreviation: CI, confidence interval.

^a No data from case series or abstracts were included in this primary analysis.

^b Data from FIT‐1 and FIT‐2 were treated as one study in meta‐analysis.

^c The I ² statistic may be biased when the number of contributing studies is small, and the 95% CI should be included in the interpretation of a point estimate.

3.5.2. Time to response and response duration

Reporting of the time to response was sparse and could not be meta‐analyzed. The FIT‐1 and FIT‐2 trials reported that the median platelet counts of both overall and stable responders reached 50 × 10⁹ cells/L by the second week of treatment [16]. These results were similar to those in the two case series where data regarding time to response was available; the seven patients in Liu and Hsia achieved an overall response by a median of 19 (range: 0–181) days, and the five patients in Mehta et al. all achieved partial responses within 1 month [21, 22]. Few studies formally reported on the duration of response; the duration of treatment was more often quantified, ranging from <1 month to 61.7 months. Of note, however, the 2019 results from the FIT‐3 open‐label study reported that among the 64 overall/stable responders (44% of the total cohort), response was maintained for a median duration ≥28 months while on fostamatinib [23]. Table S4 summarizes the time to response and duration outcomes across all included studies.

3.5.3. Relative efficacy compared to placebo

The FIT‐1, FIT‐2, and trials by Kuwana et al. represented 123 patients on fostamatinib and 61 on placebo [16, 18]. We could only compare fostamatinib and placebo for two efficacy outcomes: partial platelet response by 12 weeks of treatment and stable response by 24 weeks. Fostamatinib was favored in both comparisons, with a relative risk (RR) of 3.04 (95% CI: 1.53, 6.06, I ² = 0%, p < 0.01) for partial response (Figure 3) and a RR of 6.43 (95% CI: 1.58, 25.23, I ² = 0%, p < 0.01) for stable response (Figure 4).

FIGURE 3.

Forest plot of comparison between fostamatinib and placebo for outcome: partial platelet response (≥50 × 10⁹ cells/L) within 12 weeks of treatment. RR, relative risk.

FIGURE 4.

Forest plot of comparison between fostamatinib and placebo for outcome: stable platelet response within 24 weeks of treatment. RR, relative risk.

3.6. Safety outcomes

3.6.1. Mortality, bleeding, and VTE on fostamatinib

All‐cause mortality and VTE were both infrequent events that were not be meta‐analyzed. Across 10 studies, 8/404 (2%) deaths occurred among patients on fostamatinib and 1/61 (1%) among placebo. Across seven studies, 4/207 (2%) VTE events were reported for fostamatinib and 0/61 (0%) for placebo. Bleeding events were reported across eight studies, where no studies explicitly stated the use of ISTH criteria for bleeding events. Compared to placebo, patients on fostamatinib were less likely to experience any bleeding events (RR = 0.41, 95% CI: 0.17, 0.99) during 24 weeks of treatment (Table 3). Pooled proportion of bleeding events from the RCTs was 0.08 (95% CI: 0.03, 0.20), and the long‐term follow‐up recorded 67/146 (46%) minor events over 229.4 patient years.

TABLE 3.

Summary of adverse event comparisons between fostamatinib and placebo (24 weeks).

Outcome a	Number of studies	Fostamatinib (event/total)	Placebo (event/total)	Relative risk	95% CI	I 2 c	p
Any AE b	2	105/123	44/61	1.18	0.99, 1.40	0%	0.46
Any severe AE b	2	18/123	8/61	1.11	0.51, 2.40	0%	0.80
AE causing withdrawal from treatment	3	13/123	4/61	1.37	0.47, 4.03	0%	0.57
Rescue medication b	2	31/123	26/61	0.59	0.39, 0.90	0%	0.01
Any bleeding b	2	8/123	10/61	0.41	0.17, 0.99	0%	0.05
Hypertension b	2	37/123	7/61	2.57	1.21, 5.43	0%	0.01
Nausea b	2	20/123	4/61	2.23	0.84, 5.90	0%	0.11
Diarrhea b	2	41/123	7/61	2.69	0.98, 7.32	13%	0.05
Neutropenia b	2	10/123	0/61	5.63	0.75, 42.14	0%	0.09

Abbreviation: CI, confidence interval.

^a AE, adverse event.

^b Data from FIT‐1 and FIT‐2 were treated as one study in meta‐analysis.

^c The I ² statistic may be biased when the number of contributing studies is small, and the 95% CI should be included in the interpretation of a point estimate.

3.6.2. Rescue therapy and other AEs on fostamatinib

The most common AEs for patients on fostamatinib included the need for rescue medication (proportion = 0.30, 95% CI: 0.24, 0.37), diarrhea (proportion = 0.30, 95% CI: 0.21, 0.40), and hypertension (proportion = 0.24, 95% CI: 0.13, 0.40). Pooled proportions for all AEs are summarized in Table 2. Compared to placebo, patients on fostamatinib were less likely to require rescue medication (RR = 0.59, 95% CI: 0.39, 0.90, p = 0.01) and more likely to experience hypertension (RR = 2.57, 95% CI: 1.21, 5.43, p = 0.01) during 24 weeks of treatment. Table 3 and Figures S14–S22 summarize the comparisons between fostamatinib and placebo for other AEs during the 24 weeks of treatment. Table S5 summarizes the safety data across all included studies.

4. DISCUSSION

This systematic review summarizes the published data regarding the efficacy and safety of fostamatinib for treating adults with chronic or refractory ITP. Compared to placebo, patients on fostamatinib were 3.04 (95% CI: 1.53, 6.06) times more likely to achieve a partial response (≥50 × 10⁹ cells/L at any point) by 12 weeks of treatment and 6.43 (95% CI: 1.58, 25.23) times more likely to achieve a stable response (≥50 × 10⁹ cells/L at minimum of 66% of follow‐up visits) by 24 weeks. Mortality, bleeding, and VTE events were rare. The most common AEs included rescue therapy given to 30% (95% CI: 24%, 37%) of patients, diarrhea in 30% (95% CI: 21%, 40%), and hypertension in 24% (95% CI: 13%, 40%). Fostamatinib was associated with a 0.59 (95% CI: 0.39, 0.90) times lower risk of requiring rescue medication and a 2.57 (95% CI: 1.21, 5.43) times higher risk of hypertension in 24 weeks. The evidence is limited by heterogeneous outcomes reported across multiple small studies with no direct comparisons to other second‐ or third‐line therapies. The current data suggest that fostamatinib is a viable option for the treatment of ITP that has failed to respond to other treatments.

A recent systematic review provided an overview of clinical trials investigating tyrosine kinase inhibitors, with FIT1 and FIT2 trials as the only data for fostamatinib [24]. Our review is the first to focus on data for fostamatinib and estimate the proportion of patients who achieve clinically relevant platelet thresholds while on treatment. Our results for efficacy are similar to those from the FIT‐1 and FIT‐2 trials alone, with the observation that the proportion of partial and stable responders was higher among nonrandomized studies compared to the RCTs. This may be due to different participant characteristics; most RCT participants had already undergone multiple lines of therapy and may be affected by a disease that is inherently more refractory to treatment compared to the general population of ITP patients. The safety data of nonrandomized studies tended to concord with those of the RCTs and indicate a relatively high incidence of AEs while on fostamatinib (i.e., requiring rescue medication, hypertension, diarrhea, infection, nausea, fatigue, transaminitis, and dizziness). While these side effects may be successfully managed, they remain bothersome and may inform the decision to choose fostamatinib as a therapy.

Two network meta‐analyses have compared fostamatinib data from FIT1 and FIT2 to TPO‐RAs and ranked fostamatinib as the least efficacious but with a relatively high safety profile [25, 26]. This was theorized to be due to a combination of the fostamatinib trials’ patient composition and the single mechanism of ITP that fostamatinib targets compared to the TPO‐RAs [25, 26]. In the analyses of a network meta‐analysis (abstract only) that compared data from the FIT‐1 and FIT‐2 trials to four rituximab studies, the investigators identified fostamatinib as being associated with improved overall platelet response relative to rituximab [27]. Using data primarily from the FIT‐1 and FIT‐2 trials, major guideline groups have either positioned fostamatinib as a subsequent‐line therapy [28], or made formal recommendations for when fostamatinib may be used as a third‐line agent for refractory ITP patients nonresponsive to TPO‐RAs [29], or as a second‐line agent for some chronic ITP patients [30].

The cost of therapies for chronic ITP remains an important factor in determining the clinical treatment plan for patients. From our literature search, only one study evaluated the cost‐effectiveness of fostamatinib [30]. This economic analysis considered the costs of AEs in addition to the base cost of therapy and determined the total mean cost per patient on fostamatinib to be similar to eltrombopag and less costly compared to avatrombopag or romiplostim [30]. While underpowered for noninferiority, the results suggest that there may be economic rationale for including fostamatinib as an alternative to TPOs. However, the higher efficacy of TPO‐RAs suggests that fostamatinib will remain as a therapy subsequent to TPO‐RAs for most patients.

To support the development of guidelines, further investigation of fostamatinib with direct comparisons to other third‐ or second‐line therapies (i.e., rituximab and mycophenolate) with standardized reporting of outcomes that include duration of response will be worthwhile. The reporting of data stratified by important subgroups (e.g., duration of ITP and splenectomy status) may also clarify whether there are greater benefits to initiating fostamatinib sooner rather than later. There also remains a need for evidence‐based guidance for practitioners regarding the optimal strategies to transition patients between ITP therapies and whether there is benefit to the combination of therapies that utilize different underlying mechanisms (e.g., fostamatinib and TPO‐RAs). Ongoing studies registered to clinicaltrials.gov include NCT05502783 and NCT05509582 for fostamatinib in post‐transplant cytopenia [31, 32], NCT06071520 [33], and NCT05613296 [34].

4.1. Limitations

All studies except the RCTs were determined to have a serious risk of bias. We attempted to reduce the impact of bias by excluding case series and abstracts from primary statistical analyses, as case studies tended to report extreme proportions for efficacy and were subject to selection biases, while abstracts were not peer‐reviewed. The risk for confounding within our estimates remains high; we could not make statistical adjustments due to limited sample size and lack of stratified data within individual reports. The entire body of evidence is also at risk of publication bias due to the predominance of small studies. Although industry sources funded the majority of the included studies, a bibliographic analysis of trials in VTE prevention suggested that there may be no difference in the reporting of favorable outcomes between commercially and noncommercially funded studies [35]. Our meta‐analyses also demonstrated moderate to significant heterogeneity for nearly all pooled outcomes, as indicated by the I ² value and visual inspection of the forest plots with results stratified by study design. Even with an I ² value of 0% for our comparisons between fostamatinib and placebo, we cannot exclude heterogeneity due to the small number of studies and wide CIs. Due to the limited sample size, we did not conduct metaregression to explore causes of heterogeneity.

5. CONCLUSION

This review found that fostamatinib offers an efficacy and safety profile that makes it a viable option for providers and adult patients to consider in treating ITP refractory to previous treatments. Given the heterogeneous data and many small contributing studies, these results should be interpreted cautiously. Further prospective studies comparing fostamatinib to other third‐ and second‐line treatments are needed to clarify how fostamatinib may be used to optimize the management of ITP in this patient population.

AUTHOR CONTRIBUTIONS

Roger Kou, Lucy Zhao, and Daniel Tham conducted the research. Roger Kou, Giovanna Schünemann, and Mark Crowther designed the study. Roger Kou conducted the analysis and drafted the paper. Rachael Principato, Aqib Mannan, and Giovanna Schünemann piloted the screening and extraction phases. Roger Kou, Lucy Zhao, Daniel Tham, and Mark Crowther contributed to the editing and review of the paper.

CONFLICTS OF INTEREST STATEMENT

Roger Kou, Lucy Zhao, Daniel Tham, Rachael Principato, Aqib Mannan, and Giovanna Schünemann have no conflicts of interest to disclose. This work received no funding. In the last 36 months, Dr. Crowther has received personal funding, including but not limited to preparation of educational material, participation in Advisory Boards, or providing expert testimony for Bayer, Astra Zeneca, Pfizer, Hemostasis Reference Laboratories, Syneos Health, and Eversana. He has participated in various medicolegal activities relating to thrombosis, anticoagulant drugs, or other aspects of internal medicine and hematological practice. He has also worked with multiple organizations for‐profit and not‐for‐profit entities such as Up To Date and medical communication companies. He holds the Leo Pharma Chair in Thromboembolism, endowed at McMaster University.

FUNDING INFORMATION

This study received no funding.

ETHICS STATEMENT

The authors have confirmed ethical approval statement is not needed for this submission.

PATIENT CONSENT STATEMENT

The authors have confirmed patient consent statement is not needed for this submission.

CLINICAL TRIAL REGISTRATION

The authors have confirmed clinical trial registration is not needed for this submission.

Supporting information

Supporting Information

Kou R, Zhao L, Tham D, Principato R, Schünemann G, Mannan A, et al. Fostamatinib for immune thrombocytopenic purpura in adult patients: A systematic review and meta‐analysis. eJHaem. 2024;5:651–660. 10.1002/jha2.939

DATA AVAILABILITY STATEMENT

Available upon request.